Results 51 to 60 of about 729,378 (199)

Performance evaluation of five lipoprotein(a) immunoassays on the Roche cobas c501 chemistry analyzer

Practical Laboratory Medicine, 2021
Objectives: Measurement of lipoprotein(a) [Lp(a)] is used in risk assessment of atherosclerotic cardiovascular disease (ASCVD). The aim of the current study was to evaluate performance characteristic of five different Lp(a) assays using the cobas c501 ...
Sara P. Wyness, Jonathan R. Genzen
doaj   +1 more source

Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks. [PDF]

, 2019
BackgroundCardiovascular (CV) complications are the most significant cause of mortality in adults with Cushing disease (CD); little is known about CV risk factors in children with CD.
Belyavskaya, Elena, Cheung, Anita, De La Luz Sierra, Maria, Keil, Meg, Lodish, Maya, Lyssikatos, Charalampos, Makri, Angeliki, Remaley, Alan T, Sampson, Maureen, Sinaii, Ninet, Stratakis, Constantine A   +10 more
core  

Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study

American Journal of Preventive Cardiology, 2023
Objective: Elevated lipoprotein(a) [Lp(a)] is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and has no approved pharmacotherapies.
Xingdi Hu, Joaquim Cristino, Raju Gautam, Rina Mehta, Diana Amari, Ji Haeng Heo, Siwei Wang, Nathan D. Wong   +7 more
doaj   +1 more source

Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. [PDF]

, 2017
A single dose of the apolipoprotein (apo)A-I mimetic peptide D-4F rendered high-density lipoprotein (HDL) less inflammatory, motivating the first multiple-dose study. We aimed to assess safety/tolerability, pharmacokinetics, and pharmacodynamics of daily,
Bloedon, LeAnne T., Duffy, Danielle, Dunbar, Richard L., Fogelman, Alan M., Movva, Rajesh, Navab, Mohamad, Norris, Robert B., Rader, Daniel J.   +7 more
core   +2 more sources

Lipoprotein(a) Levels in Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation Compared to Controls

JACC: Advances
Background: Limited observational reports link elevated lipoprotein(a) (Lp[a]) levels to aortic stenosis (AS) or to disease progression. Data on large cohorts of verified severe AS patients are lacking.
Itamar Loewenstein, MD, Daniel Lichtenstein, MD, Ilana Goldiner, PhD, MHA, Jeremy Ben-Shoshan, MD, Amir Halkin, MD, Maayan Konigstein, MD, Shmuel Banai, MD, Yaron Arbel, MD, Ariel Finkelstein, MD, Arie Steinvil, MD   +9 more
doaj   +1 more source

Association between skeletal muscle mass and serum concentrations of lipoprotein lipase, GPIHBP1, and hepatic triglyceride lipase in young Japanese men [PDF]

, 2019
学位記番号 ...
Matsumoto, Ryutaro, マツモト, リュウタロウ, 松本, 隆太郎   +2 more
core  

Use of evolocumab in refractory coronary artery disease with elevated lipoprotein(a): a case report

MGM Journal of Medical Sciences
Elevated lipoprotein(a) [Lp(a)] is a well-known yet often underrecognized risk factor for atherosclerotic cardiovascular disease and recurrent coronary events.
Pulimoottil Shamsudheen Aalia, Bayana Haris, Akash Jose, Anand Kumar   +3 more
doaj   +1 more source

Lipoprotein A and the Association With Peripheral Arterial Disease: A Review of the Risk in Peripheral Arterial Disease

Reviews in Cardiovascular Medicine
Peripheral arterial disease (PAD) is a global atherosclerotic disease which can lead to acute limb ischemia, chronic limb-threatening ischemia, and limb amputation. It has similar risk factors to coronary artery disease (CAD).
Subrata Kar
doaj   +1 more source

Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting

American Journal of Preventive Cardiology
Background and aims: Different lipoprotein(a) [Lp(a)] assays may affect risk stratification of individuals and thus clinical decision-making. We aimed to investigate how transitioning between Lp(a) assays at a large central laboratory affected the ...
Janeni Jeevanathan, Sigrid M. Blom, Thomas Olsen, Kirsten B. Holven, Erik K. Arnesen, Torleif Trydal, Børge G. Nordestgaard, Michael Sovershaev, Ying Chen, Kjetil Retterstøl, Jacob J. Christensen   +10 more
doaj   +1 more source

Early stages of LDL oxidation: apolipoprotein B structural changes monitored by infrared spectroscopy. [PDF]

, 2001
Changes in the conformation of apoliprotein B-100 in the early stages of copper-mediated low density lipoprotein oxidation have been monitored by infrared spectroscopy.
Arrondo JL, Chehin, Rosana Nieves, Goñi, Félix M., Milicua, José Carlos G., Pifat, Greta, Rengel, David   +5 more
core